These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 12461170)
1. A putative molecular-activation switch in the transmembrane domain of erbB2. Fleishman SJ; Schlessinger J; Ben-Tal N Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15937-40. PubMed ID: 12461170 [TBL] [Abstract][Full Text] [Related]
2. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations. Sajot N; Genest M J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846 [TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER receptor protein-tyrosine kinases and cancer. Roskoski R Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434 [TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent oligomerization of the Neu transmembrane domain suggests inhibition of "conformational switching" by an oncogenic mutant. Beevers AJ; Damianoglou A; Oates J; Rodger A; Dixon AM Biochemistry; 2010 Apr; 49(13):2811-20. PubMed ID: 20180588 [TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulations of the transmembrane domain of the oncogenic ErbB2 receptor dimer in a DMPC bilayer. Garnier N; Crouzy S; Genest M J Biomol Struct Dyn; 2003 Oct; 21(2):179-200. PubMed ID: 12956604 [TBL] [Abstract][Full Text] [Related]
6. The single transmembrane domains of ErbB receptors self-associate in cell membranes. Mendrola JM; Berger MB; King MC; Lemmon MA J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943 [TBL] [Abstract][Full Text] [Related]
7. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. Mineev KS; Bocharov EV; Pustovalova YE; Bocharova OV; Chupin VV; Arseniev AS J Mol Biol; 2010 Jul; 400(2):231-43. PubMed ID: 20471394 [TBL] [Abstract][Full Text] [Related]
8. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. Kunz C; Borghouts C; Buerger C; Groner B Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388 [TBL] [Abstract][Full Text] [Related]
9. A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer? Groenen LC; Walker F; Burgess AW; Treutlein HR Biochemistry; 1997 Apr; 36(13):3826-36. PubMed ID: 9092812 [TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of c-erbB2 receptor dimerization: coiled-coil structure of wild and oncogenic transmembrane domains--stabilization by interhelical hydrogen bonds in the oncogenic form. Garnier N; Genest D; Duneau JP; Genest M Biopolymers; 1997 Aug; 42(2):157-68. PubMed ID: 9234995 [TBL] [Abstract][Full Text] [Related]
11. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure. Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496 [TBL] [Abstract][Full Text] [Related]
12. ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927 [TBL] [Abstract][Full Text] [Related]
13. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853 [TBL] [Abstract][Full Text] [Related]
14. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. Penuel E; Akita RW; Sliwkowski MX J Biol Chem; 2002 Aug; 277(32):28468-73. PubMed ID: 12000754 [TBL] [Abstract][Full Text] [Related]
15. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376 [TBL] [Abstract][Full Text] [Related]
16. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Neve RM; Sutterlüty H; Pullen N; Lane HA; Daly JM; Krek W; Hynes NE Oncogene; 2000 Mar; 19(13):1647-56. PubMed ID: 10763821 [TBL] [Abstract][Full Text] [Related]
17. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Zhan L; Xiang B; Muthuswamy SK Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444 [TBL] [Abstract][Full Text] [Related]
18. Effects of the oncogenic V(664)E mutation on membrane insertion, structure, and sequence-dependent interactions of the Neu transmembrane domain in micelles and model membranes: an integrated biophysical and simulation study. Beevers AJ; Nash A; Salazar-Cancino M; Scott DJ; Notman R; Dixon AM Biochemistry; 2012 Mar; 51(12):2558-68. PubMed ID: 22385253 [TBL] [Abstract][Full Text] [Related]
19. A dimerization hierarchy in the transmembrane domains of the HER receptor family. Duneau JP; Vegh AP; Sturgis JN Biochemistry; 2007 Feb; 46(7):2010-9. PubMed ID: 17253768 [TBL] [Abstract][Full Text] [Related]
20. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]